The Israeli trials are for company’s CF-101 drug for the treatment of dry-eye syndrome.
Can-Fite BioPharma Ltd. (TASE:CFBI) today announced that the Ministry of Health has given it permission to conduct Phase II clinical trials for its CF-101 drug for the treatment of keratitis sicca (dry-eye syndrome).
The trial will include 50 patients at medical centers across Israel. The results of the trial will be sent to the US Food and Drug Administration (FDA), and Can-Fite believes that a successful trial in Israel will facilitate the registration of the drug in other countries.
Keratitis sicca is caused by inflammation of the tear ducts, as a side effect of rheumatoid arthritis, especially Sjorgren’s Syndrome. Over 30 million people currently suffer from keratitis sicca, and there is no effective treatment.
Published by Globes [online], Israel business news - www.globes.co.il - on September 5, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006